Study of ticagrelor for stroke-related blood vessel disease
Part of Brain & nervous system, Heart & circulation clinical trials.
This study looks at how well ticagrelor works in people with ischemic cerebrovascular disease (strokes or “clogged blood vessel” brain problems) in everyday real-world care. It also monitors side effects, especially bleeding-related issues, to see what adverse reactions happen.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 years or older.
- You have a clinician diagnosis of ischemic cerebrovascular disease.
- You are currently taking ticagrelor (a blood thinner/anti-platelet medicine).
- You can understand the study and sign informed consent.
- Your recent CT or MRI does not suggest bleeding in the brain.
- You do not have a known allergy to ticagrelor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests whether low-dose colchicine added to ticagrelor (a blood-thinning medicine) helps prevent another ischemic stroke in people whose first stroke was caused by clogged arteries. It aims to lower the risk of repeat stroke after recovery from a recent event.
This trial tests whether switching to a simpler antiplatelet medication (ticagrelor) after a mild stroke or high-risk TIA can prevent another stroke while reducing the risk of bleeding. It is for people who have not received clot-busting treatment or had a large stroke.
This study compares two blood thinner medicines, ticagrelor and cilostazol, to see which is better at preventing another stroke in people who have just had a minor stroke or TIA (a mini-stroke). It is for people who started treatment within 24 hours of their symptoms.
This trial compares two antiplatelet drugs (ticagrelor and cilostazol) to see which is better at preventing another stroke in people who have had a large-vessel ischemic stroke. Both drugs help keep blood clots from forming, and the study aims to find the safest and most effective option for patients who cannot receive clot-busting medication.
This trial tests whether adding aspirin to either ticagrelor or clopidogrel (two antiplatelet medicines) can help prevent another stroke in people who recently had a minor stroke or TIA affecting a large brain artery. It is for people who started antiplatelet treatment within 24 hours of their symptoms.
This study tests whether guiding antiplatelet medication with a blood test can help prevent another stroke or TIA. It looks at people who have had a mild stroke or high-risk TIA within the last 48 hours.
Hear when a new Cerebral Infarction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.